$10.98
1.20% yesterday
Nasdaq, Jul 11, 10:04 pm CET
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Cogent Biosciences Inc Stock price

$10.98
+3.72 51.24% 1M
+3.41 45.05% 6M
+3.18 40.77% YTD
+1.84 20.13% 1Y
+0.23 2.14% 3Y
-2.14 16.31% 5Y
-33.46 75.29% 10Y
-33.46 75.29% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
+0.13 1.20%
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.2b
Net debt
positive
Cash
$246.0m
Shares outstanding
114.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
78.1%
Return on Equity
-78.5%
ROCE
-122.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-285.5m | $-210.3m
EBIT
$-288.0m | $-285.3m
Net Income
$-202.0m | $-246.1m
Free Cash Flow
$-223.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-27.1% | 23.1%
EBIT
-26.9% | -3.4%
Net Income
-1.1% | -22.4%
Free Cash Flow
-32.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-2.0
Short interest
17.0%
Employees
205
Rev per Employee
$0.0
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Cogent Biosciences Inc forecast:

14x Buy
78%
4x Hold
22%

Analyst Opinions

18 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
78%
Hold
22%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
25% 25%
-
- Research and Development Expense - -
-
-
-286 -286
27% 27%
-
- Depreciation and Amortization 2.49 2.49
6% 6%
-
EBIT (Operating Income) EBIT -288 -288
27% 27%
-
Net Profit -202 -202
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Neutral
GlobeNewsWire
one day ago
WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to t...
Positive
Seeking Alpha
3 days ago
I have upgraded Cogent Biosciences, Inc. to Strong Buy after positive SUMMIT trial data for bezuclastinib in non-advanced systemic mastocytosis patients. COGT plans to submit an NDA for bezuclastinib in NonAdvSM by end of 2025, with additional pivotal data readouts expected in AdvSM and GIST in 2nd half 2025. Cogent is well-funded, raising $200M recently and maintaining a cash runway into late ...
Neutral
GlobeNewsWire
3 days ago
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The a...
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 205
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today